

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III NIAGARA trial investigated the efficacy of which of the following agents in combination with gemcitabine and cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer?**
 - a. Avelumab
 - b. Atezolizumab
 - c. Durvalumab**
 - d. Both b and c
- 2. Which of the following statements best describes the safety outcomes for patients who received datopotamab deruxtecan and rilvegostomig in the Phase II TROPION-PanTumor03 study?**
 - a. Grade 5 adverse events were reported with this combination
 - b. The safety profile of the combination was consistent with previous reports investigating this combination**
 - c. The incidence of serious treatment-related adverse events was higher in the first-line cisplatin-ineligible patient group
 - d. Grade 3 or higher interstitial lung disease was observed in patients receiving the combination in the second-line setting
- 3. Which of the following statements best describes the progression-free survival outcomes reported in the Phase II DESTINY-PanTumor02 trial for patients with bladder cancers treated with trastuzumab deruxtecan?**
 - a. Outcomes were worse for patients with HER2-expressing disease
 - b. Outcomes were improved for only those patients whose disease was HER2 IHC 3+
 - c. Outcomes were improved for patients with HER2-expressing disease — HER2 IHC 2+ or 3+**
- 4. What was the approximate confirmed overall response rate for patients with HER2 IHC 3+ bladder cancers treated with trastuzumab deruxtecan in the Phase II DESTINY-PanTumor02 trial?**
 - a. Lower than 26%
 - b. 36%
 - c. 56%**
 - d. Higher than 66%
- 5. According to findings reported in the Phase III RC48-C016 trial, what was the approximate relative reduction in the risk of disease progression or death for patients with advanced or metastatic urothelial bladder cancer treated with disitamab vedotin?**
 - a. 24%
 - b. 44%
 - c. 64%**
 - d. 84%